Therapeutic strategies in HCC: Radiation modalities

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Gallicchio, R ^a   Nardelli, A ^b   Mainenti, P ^b   Nappi, A ^a   Capacchione, D ^a   Simeon, V ^a   Sirignano, C ^b   Abbruzzi, F ^c   Barbato, F ^d   Landriscina, M ^a,e   Storto, G ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CNR   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d CMO Oplonti Medical Centre   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; MICROSPHERE; MICROSPHERE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CHEMOEMBOLIZATION; CONFORMAL RADIOTHERAPY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IONIZING RADIATION; LIVER CELL CARCINOMA; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRAM COST EFFECTIVENESS; RADIATION DOSE; REVIEW; TRANSARTERIAL METABOLIC RADIOTHERAPY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; WORKPLACE; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; LIVER; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMORADIOTHERAPY; HUMANS; LIVER; LIVER NEOPLASMS;

EID: 84983490241     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/1295329     Document Type: Review

References (102)

1. R. Dhanasekaran, A. Limaye, and R. Cabrera, "Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics," Hepatic Medicine: Evidence and Research, Vol. 4, pp. 19-37, 2012.
2. Surveillance Research Program, National Cancer Institute Fast stats: an interactive tool for access to SEER cancer statistics, November 2011, http://seer.cancer.gov/faststats.
3. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008," International Journal of Cancer, Vol. 127, no. 12, pp. 2893-2917, 2010.
4. K. Okuda, "Hepatocellular carcinoma," Journal of Hepatology, Vol. 32, no. 1, supplement, pp. 225-237, 2000.
5. H. B. El-Serag and A. C. Mason, "Rising incidence of hepatocellular carcinoma in the United States," The New England Journal of Medicine, Vol. 340, no. 10, pp. 745-750, 1999.
6. S. Deuffic, L. Buffiat, T. Poynard, and A. J. Valleron, "Modeling the hepatitis C virus epidemic in France," Hepatology, Vol. 29, no. 5, pp. 1596-1601, 1999.
7. M. C. Wallace, D. Preen, G. P. Jeffrey, and L. A. Adams, "The evolving epidemiology of hepatocellular carcinoma: a global perspective," Expert Review of Gastroenterology and Hepatology, Vol. 9, no. 6, pp. 765-779, 2015.
8. T. P. Hong, P. Gow, M. Fink et al., "Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed," Hepatology, Vol. 63, no. 4, pp. 1205-1212, 2016.
9. K. Joshi, M. Mendler, R. Gish et al., "Hepatocellular carcinoma surveillance: a national survey of current practices in the USA," Digestive Diseases and Sciences, Vol. 59, no. 12, pp. 3073-3077, 2014.
10. R. Lencioni, "Chemoembolization in patients with hepatocellular carcinoma," Liver Cancer, Vol. 1, no. 1, pp. 41-50, 2012.
11. E. Liapi and J.-F. Geschwind, "Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer," Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 17, no. 4, pp. 405-406, 2010.
12. W. D. Hsiao, C. Y. Peng, P. H. Chuang et al., "Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study," BMC Gastroenterology, Vol. 16, no. 1, p. 50, 2016.
13. T. Yamasaki, S. Hamabe, I. Saeki et al., "A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial," Journal of Gastroenterology, Vol. 46, no. 3, pp. 359-366, 2011.
14. L. Vadot, M. Boulin, B. Guiu et al., "Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma," Journal of Clinical Pharmacy and Therapeutics, Vol. 40, no. 1, pp. 83-90, 2015.
15. S. C. H. Yu, J. W. Y. Hui, E. P. Hui et al., "Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization," Radiology, Vol. 270, no. 2, pp. 607-620, 2014.
16. G. F. Stefanini, P. Amorati, M. Biselli et al., "Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience," Cancer, Vol. 75, no. 10, pp. 2427-2434, 1995.
17. G. Pelletier, A. Roche, O. Ink et al., "A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma," Journal of Hepatology, Vol. 11, no. 2, pp. 181-184, 1990.
18. 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a multicenter retrospective cohort study," Journal of Nuclear Medicine, Vol. 57, no. 4, pp. 509-516, 2016.
19. A. Lintia-Gaultier, C. Perret, C. Ansquer, T. Eugène, F. Kraeber Bodéré, and E. Frampas, "Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience," Nuclear Medicine Communications, Vol. 34, no. 7, pp. 674-681, 2013.
20. S. Subramanian, T. Das, S. Chakraborty et al., "Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: A Preliminary Animal Study," Cancer Biotherapy and Radiopharmaceuticals, Vol. 25, no. 5, pp. 539-543, 2010.
21. B. Lambert, K. Bacher, and L. Defreyne, "Rhenium-188 based radiopharmaceuticals for treatment of liver tumours," Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 53, no. 3, pp. 305-310, 2009.
22. T. Das, S. Chakraborty, H. D. Sarma, M. Venkatesh, and S. Banerjee, "Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer," Nuclear Medicine Communications, Vol. 30, no. 5, pp. 362-367, 2009.
23. J. Yu, U. O. Häfeli, M. Sands, and Y. Dong, "90Y-oxineethiodol, a potential radiopharmaceutical for the treatment of liver cancer," Applied Radiation and Isotopes, Vol. 58, no. 5, pp. 567-573, 2003.
24. S. Ho, J. W. Y. Lau, T. W. T. Leung, J. E. Dancey, and J. Goin, "Intrahepatic 90Y-microspheres for hepatocellular carcinoma," Journal of Nuclear Medicine, Vol. 42, no. 10, pp. 1587-1589, 2001.
25. Z.-C. Zeng, Z.-Y. Tang, K.-D. Liu, J.-Z. Lu, H. Xie, and Z. Yao, "Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials," Journal of Cancer Research and Clinical Oncology, Vol. 124, no. 5, pp. 275-280, 1998.
26. J. Liebster and V. Kočandrle, "Exchange labelling of 'lipiodol' ultra fluids with lodine-131 and its intra-lymphatic administration with a fistula on the thoracic duct," Nature, Vol. 203, no. 4946, pp. 777-778, 1964.
27. J. L. Raoul, R. Duvauferrier, P. Bourguet et al., "Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled Lipiodol," Journal de Radiologie, Vol. 67, no. 11, pp. 797-801, 1986.
28. D. M. Biederman, J. J. Titano, K. M. Lee et al., "Yttrium-90 glassbased microsphere radioembolization in the treatment of hep atocellular carcinoma secondary to the hepatitis B virus: safety, efficacy, and survival," Journal of Vascular and Interventional Radiology, Vol. 26, no. 11, pp. 1630-1638, 2015.
29. N. Khajornjiraphan, N. A. Thu, and P. K. Chow, "Yttrium-90 microspheres: a review of its emerging clinical indications," Liver Cancer, Vol. 4, no. 1, pp. 6-15, 2015.
30. M. Xi, M.-Z. Liu, X.-W. Deng et al., "Defining internal target volume (ITV) for hepatocellular carcinoma using fourdimensional CT," Radiotherapy and Oncology, Vol. 84, no. 3, pp. 272-278, 2007.
31. R. P. Beasley, C.-C. Lin, L.-Y. Hwang, and C.-S. Chien, "Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan," The Lancet, Vol. 318, no. 8256, pp. 1129-1133, 1981.
32. I. H. McKillop, D. M. Moran, X. Jin, and L. G. Koniaris, "Molecular pathogenesis of hepatocellular carcinoma," Journal of Surgical Research, Vol. 136, no. 1, pp. 125-135, 2006.
33. C. Guha and B. D. Kavanagh, "Hepatic radiation toxicity: avoidance and amelioration," Seminars in Radiation Oncology, Vol. 21, no. 4, pp. 256-263, 2011.
34. C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, and D. I. Kim, "Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma therapeutic feasibility study," Clinical Nuclear Medicine, Vol. 11, no. 7, pp. 514-517, 1986.
35. F. I. Chou, K. C. Fang, C. Chung et al., "Lipiodol uptake and retention by human hepatoma cells," Nuclear Medicine and Biology, Vol. 22, no. 3, pp. 379-386, 1995.
36. C. Park, S. I. Choi, H. Kim, H. S. Yoo, and Y. B. Lee, "Distribution of Lipiodol in hepatocellular carcinoma," Liver, Vol. 10, no. 2, pp. 72-78, 1990.
37. R. E. Hind, M. Loizidou, S. Perring et al., "Biodistribution of Lipiodol following hepatic arterial injection," British Journal of Surgery, Vol. 79, no. 9, pp. 952-954, 1992.
38. M. Nakajo, H. Kobayashi, K. Shimabukuro et al., "Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer," Journal of Nuclear Medicine, Vol. 29, no. 6, pp. 1066-1077, 1988.
39. P. Bernal, J.-L. Raoul, J. Stare et al., "International atomic energy agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study," Seminars in Nuclear Medicine, Vol. 38, no. 2, pp. S40-S45, 2008.
40. P. Bernal, J.-L. Raoul, G. Vidmar et al., "Intra-arterial rhenium188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-Sponsored Multination Study," International Journal of Radiation Oncology Biology Physics, Vol. 69, no. 5, pp. 1448-1455, 2007.
41. 188Re-TDD, for the treatment of liver cancer," Nuclear Medicine and Biology, Vol. 28, no. 2, pp. 197-204, 2001.
42. S.-J. Wang, W.-Y. Lin, W.-Y. Lui, M.-N. Chen, Z.-T. Tsai, and G. Ting, "Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatoma," Journal of Nuclear Medicine, Vol. 37, no. 2, pp. 332-335, 1996.
43. V. Vilgrain, M. Abdel-Rehim, A. Sibert et al., "Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial," Trials, Vol. 15, article 474, 2014.
44. S. A. Gulec, G. Mesoloras, W. A. Dezarn, P. McNeillie, and A. S. Kennedy, "Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio," Journal of Translational Medicine, Vol. 5, article 15, 2007.
45. W.-Y. Lau, W.-T. Leung, S. Ho et al., "Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study," British Journal of Cancer, Vol. 70, no. 5, pp. 994-999, 1994.
46. A. Nardelli, E. Castaldi, G. Ortosecco et al., "Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90," Applied Radiation and Isotopes, Vol. 69, no. 1, pp. 52-55, 2011.
47. G. Storto, A. De Renzo, T. Pellegrino et al., "Assessment of metabolic response to radioimmunotherapy with 90Yibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma," Radiology, Vol. 254, no. 1, pp. 245-252, 2010.
48. H. Sharma, "Role of external beam radiation therapy in management of hepatocellular carcinoma," Journal of Clinical and Experimental Hepatology, Vol. 4, supplement 3, pp. S122-S125, 2014.
49. Y. Tanaka, T. Nakazawa, S. Komori et al., "Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes," Journal of Gastroenterology and Hepatology, Vol. 29, no. 2, pp. 352-357, 2014.
50. T. S. Lawrence, M. L. Kessler, and J. M. Robertson, "Conformal high-dose radiation plus intraarterial floxuridine for hepatic cancer," Oncology, Vol. 7, no. 10, pp. 51-57, 1993.
51. J. M. Robertson, T. S. Lawrence, J. C. Andrews, S. Walker, M. L. Kessler, and W. D. Ensminger, "Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers," International Journal of Radiation Oncology, Biology, Physics, Vol. 37, no. 2, pp. 325-330, 1997.
52. S. H. Bae, M.-S. Kim, C. K. Cho, K. B. Kim, C. J. Han, and Y. H. Kim, "Feasibility and efficacy of stereotactic ablative radiotherapy for: Barcelona clinic liver cancer-C stage hepatocellular carcinoma," Journal of Korean Medical Science, Vol. 28, no. 2, pp. 213-219, 2013.
53. A. Bujold, C. A. Massey, J. J. Kim et al., "Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma," Journal of Clinical Oncology, Vol. 31, no. 13, pp. 1631-1639, 2013.
54. W.-Y. Huang, Y.-M. Jen, M.-S. Lee et al., "Stereotactic body radiation therapy in recurrent hepatocellular carcinoma," International Journal of Radiation Oncology, Biology, Physics, Vol. 84, no. 2, pp. 355-361, 2012.
55. H. R. Cárdenes, T. R. Price, S. M. Perkins et al., "Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma," Clinical and Translational Oncology, Vol. 12, no. 3, pp. 218-225, 2010.
56. J. H. Kwon, S. H. Bae, J. Y. Kim et al., "Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer," BMC Cancer, Vol. 10, article 475, 2010.
57. Y. S. Seo, M.-S. Kim, S. Y. Yoo et al., "Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma," Journal of Surgical Oncology, Vol. 102, no. 3, pp. 209-214, 2010.
58. A. W. Katz, S. Chawla, Z. Qu, R. Kashyap, M. T. Milano, and A. F. Hezel, "Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation," International Journal of Radiation Oncology Biology Physics, Vol. 83, no. 3, pp. 895-900, 2012.
59. J. K. O'Connor, J. Trotter, G. L. Davis, J. Dempster, G. B. Klintmalm, and R. M. Goldstein, "Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation," Liver Transplantation, Vol. 18, no. 8, pp. 949-954, 2012.
60. A. Al-Kalbani and Y. Kamel, "Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma," Saudi Journal of Gastroenterology, Vol. 14, no. 2, pp. 90-92, 2008.
61. J.-L. Raoul, D. Guyader, J.-F. Bretagne et al., "Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support," Journal of Nuclear Medicine, Vol. 35, no. 11, pp. 1782-1787, 1994.
62. W. Y. Lau, T. W. T. Leung, S. K. W. Ho et al., "Adjuvant intraarterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial," The Lancet, Vol. 353, no. 9155, pp. 797-801, 1999.
63. R. T.-P. Poon, S.-T. Fan, I. O.-L. Ng, C.-M. Lo, C.-L. Liu, and J. Wong, "Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma," Cancer, Vol. 89, no. 3, pp. 500-507, 2000.
64. T. S. Su, P. Liang, H. Z. Lu et al., "Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients," Journal of Surgical Oncology, Vol. 113, no. 2, pp. 181-187, 2016.
65. T. Kimura, H. Aikata, S. Takahashi et al., "Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies," Hepatology Research, Vol. 45, no. 4, pp. 378-386, 2015.
66. N. Sanuki, A. Takeda, Y. Oku et al., "Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients," Acta Oncologica, Vol. 53, no. 3, pp. 399-404, 2014.
67. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma," Journal of Hepatology, Vol. 56, no. 4, pp. 908-943, 2012.
68. C. L. Maini, M. G. Scelsa, C. Fiumara et al., "Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma," Clinical Nuclear Medicine, Vol. 21, no. 3, pp. 221-226, 1996.
69. T. de Baere, P. Taourel, J. M. Tubiana et al., "Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow," Radiology, Vol. 212, no. 3, pp. 665-668, 1999.
70. C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, D. I. Kim, and B. S. Kim, "Treatment of hepatocellular carcinoma (HCC), with radiolabeled lipiodol: A Preliminary Report," Nuclear Medicine Communications, Vol. 8, no. 12, pp. 1075-1087, 1987.
71. H. S. Yoo, C. H. Park, J. T. Lee et al., "Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol," Cancer Chemotherapy and Pharmacology, Vol. 33, no. 1, pp. S128-S133, 1994.
72. Y. Yumoto, K. Jinno, S. Inatsuki et al., "Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution," Cancer Chemotherapy and Pharmacology, Vol. 31, no. 1, pp. S128-S136, 1992.
73. N. Heger, S. Bayindir, R. Steckenmesser, and H. Schirmer, "Percutaneous catheter-arteriographies: seldinger technique," Minnesota Medicine, Vol. 53, no. 10, pp. 1093-1097, 1970.
74. N. Iwata, Y. Seto, and E. Kakishita, "Radiation hepatitis," Ryōikibetsu Shōkōgun Shirīzu, Vol. 8, pp. 588-590, 1995.
75. J.-F. Bretagne, J.-L. Raoul, P. Bourguet et al., "Hepatic artery injection of I-131-labeled Lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases," Radiology, Vol. 168, no. 2, pp. 547-550, 1988.
76. Y. Kondo, O. Kimura, and T. Shimosegawa, "Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma," World Journal of Gastroenterology, Vol. 21, no. 1, pp. 94-101, 2015.
77. H. S. Yoo, J. T. Lee, K. W. Kim et al., "Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil," Cancer, Vol. 68, no. 9, pp. 1878-1884, 1991.
78. H. S. Yoo, C. H. Park, J. H. Suh et al., "Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings," Cancer Chemotherapy and Pharmacology, Vol. 23, no. 1, pp. S54-S58, 1989.
79. T. Torizuka, N. Tamaki, T. Inokuma et al., "Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy," Journal of Nuclear Medicine, Vol. 35, no. 12, pp. 1965-1969, 1994.
80. G. Storto, E. Nicolai, and M. Salvatore, "[18F]FDG-PET-CT for early monitoring of tumor response: when and why," Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 53, no. 2, pp. 167-180, 2009.
81. F. Maddalena, G. Lettini, R. Gallicchio et al., "Evaluation of glucose uptake in normal and cancer cell lines by positron emission tomography," Molecular Imaging, Vol. 14, no. 8, pp. 490-498, 2015.
82. B. Lambert and C. Van de Wiele, "Treatment of hepatocellular carcinoma by means of radiopharmaceuticals," European Journal of Nuclear Medicine and Molecular Imaging, Vol. 32, no. 8, pp. 980-989, 2005.
83. J. I. Raoul, J. F. Bretagne, J. P. Caucanas et al., "Internal radiation therapy for hepatocellular carcinoma: results of a French multicenter Phase II trial of transarterial injection of iodine 131-labeled Lipiodol," Cancer, Vol. 69, no. 2, pp. 346-352, 1992.
84. K. Memon, R. J. Lewandowski, A. Riaz, and R. Salem, "Yttrium 90 microspheres for the treatment of hepatocellular carcinoma," Recent Results in Cancer Research, Vol. 190, pp. 207-224, 2013.
85. S. M. Ibrahim, L. Kulik, T. Baker et al., "Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium90 radioembolization," CardioVascular and Interventional Radiology, Vol. 35, no. 5, pp. 1094-1101, 2012.
86. Y. Kimdo, B. J. Park, Y. H. Kim et al., "Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study," American Journal of Clinical Oncology, Vol. 38, no. 5, pp. 495-501, 2015.
87. B. Sangro, J. I. Bilbao, J. Boan et al., "Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma," International Journal of Radiation Oncology Biology Physics, Vol. 66, no. 3, pp. 792-800, 2006.
88. J. Edeline, L. Crouzet, B. Campillo-Gimenez et al., "Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis," European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, no. 4, pp. 635-643, 2016.
89. L. Kulik and R. Salem, "Downstaging: looking for answers, generating more questions?" Liver Transplantation, Vol. 21, no. 9, pp. 1117-1119, 2015.
90. W. Y. Lau, S. Ho, T. W. T. Leung et al., "Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres," International Journal of Radiation Oncology Biology Physics, Vol. 40, no. 3, pp. 583-592, 1998.
91. W. Park, D. H. Lim, S. W. Paik et al., "Local radiotherapy for patients with unresectable hepatocellular carcinoma," International Journal of Radiation Oncology Biology Physics, Vol. 61, no. 4, pp. 1143-1150, 2005.
92. F. Mornex, N. Girard, C. Beziat et al., "Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma noneligible for curative therapies-mature results of the French Phase II RTF-1 trial," International Journal of Radiation Oncology, Biology, Physics, Vol. 66, no. 4, pp. 1152-1158, 2006.
93. J.-L. Raoul, D. Guyader, J.-F. Bretagne et al., "Prospective randomized trial of chemoembolization versus intraarterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma," Hepatology, Vol. 26, no. 5, pp. 1156-1161, 1997.
94. B. Brans, K. Van Laere, F. Gemmel et al., "Combining iodine131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma," European Journal of Nuclear Medicine, Vol. 29, no. 7, pp. 928-932, 2002.
95. B. Gray, G. Van Hazel, M. Hope et al., "Randomised trial of SIRSpheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer," Annals of Oncology, Vol. 12, no. 12, pp. 1711-1720, 2001.
96. M. B. Pitton, R. Kloeckner, C. Ruckes et al., "Randomized comparison of selective internal radiotherapy (SIRT) versus drugeluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma," CardioVascular and Interventional Radiology, Vol. 38, no. 2, pp. 352-360, 2015.
97. F. T. Kolligs, J. I. Bilbao, T. Jakobs et al., "Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma," Liver International, Vol. 35, no. 6, pp. 1715-1721, 2015.
98. E. Ben-Josef, D. Normolle, W. D. Ensminger et al., "Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies," Journal of Clinical Oncology, Vol. 23, no. 34, pp. 8739-8747, 2005.
99. P. K. H. Chow, D. Y. H. Poon, M.-W. Khin et al., "Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma," PLoS ONE, Vol. 9, no. 3, Article ID e90909, 2014.
100. J. Ricke, K. Bulla, F. Kolligs et al., "Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC," Liver International, Vol. 35, no. 2, pp. 620-626, 2015.
101. P. Pedicini, R. Caivano, B. A. Jereczek-Fossa et al., "Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors," Teoretical Biology and Medical Modelling, Vol. 9, article 23, 2012.
102. P. Pedicini, A. Nappi, L. Strigari et al., "Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma," Radiation Oncology, Vol. 7, article 143, 2012.